Trial Profile

Phase 4, multicenter, prospective, observational two-part 3-Year Longitudinal Registry and study of AUSTEDO (deutetrabenazine) for tardive dyskinesia (TD)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Nov 2025 Interim results presented in the Teva Pharmaceuticals Media Release.
07 Nov 2025 According to a Teva Pharmaceuticals media release, the interim analysis from Part B of the IMPACT-TD Registry evaluating 27 adults with TD treated with AUSTEDO or AUSTEDO XR after a three-month period using IMPACT-TD PRO, a 30-question scale were presented at the 2025 Neuroscience Education Institute Fall Congress, taking place November 6- 9, 2025 in Colorado Springs, Colorado.
01 Nov 2024 According to a Teva Pharmaceuticals media release, interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR are being presented at the Psych Congress 2024 taking place from October 29 -November 2 in Boston, MA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com